Neoleukin Therapeutics, Inc. announced resignation of Robert Ho as Chief Financial Officer to pursue another opportunity, effective March 1, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.72 USD | +1.32% | +18.95% | +94.63% |
06-03 | Neurogene's Gene Therapy For Rett Syndrome Picked For FDA Pilot Program | MT |
06-03 | Neurogene Inc. Announces NGN-401 Gene Therapy for Rett Syndrome Selected by FDA for Start Pilot Program | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+94.63% | 490M | |
+46.19% | 55.7B | |
-6.14% | 39.57B | |
+39.84% | 39.91B | |
-6.65% | 28.16B | |
+12.33% | 26.3B | |
-21.78% | 18.94B | |
-0.35% | 12.12B | |
+24.18% | 12.12B | |
+28.38% | 12.17B |
- Stock Market
- Equities
- NGNE Stock
- News Neurogene Inc.
- Neoleukin Therapeutics, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective March 1, 2022